AstraZeneca plc 11.9% Potential Upside Indicated by Deutsche Bank

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Deutsche Bank. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 8300 GBX on its stock. This is indicating the analyst believes there is a potential upside of 11.9% from the opening price of 7419 GBX. Over the last 30 and 90 trading days the company share price has decreased 81 points and decreased 164 points respectively. The 1 year high for the share price is 7948 GBX while the 52 week low for the share price is 5626 GBX.

AstraZeneca plc has a 50 day moving average of 9,088.40 GBX and a 200 Day Moving Average share price is recorded at 7,497.12. There are currently 1,312,187,447 shares in issue with the average daily volume traded being 1,980,530. Market capitalisation for LON:AZN is £96,865,677,337 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search